Many promising drug programs fail because critical factors like formulation, dose, and market need are considered too late. Addressing these factors early by starting with the patient in mind helps select the right molecule and avoid costly failures in the gap between discovery and IND-enabling studies.
The primary advantage of cell-free protein synthesis isn't just speed for early material generation. Its real power lies in facilitating a rapid 'design-build-test' cycle, allowing teams to quickly engineer and validate multiple molecular variants against specific design criteria before committing to a final candidate.
In bioprocessing, it is more efficient to design a development process that accommodates the constraints of the manufacturing facility. Forcing a plant to adapt to a rigid process is difficult and costly. This includes making early, scalable choices about materials like chromatography resins to ensure a smooth tech transfer.
For resource-limited startups, the most critical early investment is ensuring drug stability. A stable molecule not only improves viability for later development stages but also preserves the integrity of retained samples. These samples are invaluable for bridging studies and future analysis as the program matures.